"Patients with metastatic hormone-sensitive prostate cancer benefited from treatment with darolutamide plus ADT and docetaxel ...
The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.
“Interestingly, the confirmed response rate in the intention to treat population was 32%, but this increases to 53% in the MET driven subset,” says Francesca Jackson-Spence, MBChB, BMedSc, MRCP. In ...
Disitamab vedotin plus toripalimab demonstrated a 63.6% pathologic complete response rate in HER2-expressing MIBC patients. The 12-month event-free survival rate was 92.5%, indicating promising ...
“Both groups benefited, but it would look like earlier is better if we can treat patients with low-volume disease,” says Fred Saad, MD, FRCS In this video, Fred Saad, MD, FRCS, shares key findings ...
ARPIs provide significant survival benefits in younger mHSPC patients, with a 13% improvement in 5-year overall survival and 21% in progression-free survival. The meta-analysis included data from 11 ...
Talazoparib and enzalutamide combination significantly improved overall survival in mCRPC patients compared to enzalutamide and placebo. The TALAPRO-2 study showed a median overall survival of 45.8 ...
Avelumab plus BSC significantly prolongs OS and PFS in advanced urothelial carcinoma, regardless of diabetes mellitus status. The study included 700 patients, with a balanced distribution of diabetes ...
"I think this is the next step for testing the clinical activity of this agent," says David A. Braun, MD, PhD. In this video, David A. Braun, MD, PhD, describes background and design of the phase 2 ...
Darolutamide demonstrated longer treatment duration and delayed progression to metastatic CRPC compared to enzalutamide and apalutamide in Black and White patients. The DEAR and DEAR-EXT studies ...
"The median progression-free survival and median overall survival continue to be almost double what we see with chemotherapy," says Gopa Iyer, MD. In this video, Gopa Iyer, MD, shares findings from an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results